[Comment] Considering quantity and quality of life in metastatic castration-naive prostate cancer

The treatment approach for metastatic prostate cancer is rapidly evolving. Drugs that were previously used primarily in the setting of castration-resistant prostate cancer have now been shown to improve survival in castration-naive disease. Specifically, both abiraterone acetate (in combination with prednisone)1,2 and docetaxel3 have been shown to confer an overall survival advantage when used with androgen deprivation therapy (ADT) in patients with metastatic castration-naive prostate cancer. Although these are promising developments, it is important that these treatments improve both quantity and quality of life in patients.

Source: The Lancet Oncology - January 8, 2018 Category: Cancer & Oncology Authors: David F Penson Tags: Comment Source Type: research